| Authors: |
Richardson PG; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Oriol A; Institut Català d'Oncologia and Josep Carreras Research Institute, Hospital Germans Trias i Pujol, Badalona, Spain., Larocca A; Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza, Torino, Italy., Bladé J; Hematology Department, IDIBAPS, Hospital Clinic, Barcelona, Spain., Cavo M; Seràgnoli Institute of Hematology, Bologna University School of Medicine, Bologna, Italy., Rodriguez-Otero P; Clínica Universidad de Navarra, Pamplona, Spain., Leleu X; CHU de Poitiers, Poitiers, France., Nadeem O; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Hiemenz JW; Division of Hematology-Oncology, Department of Medicine, University of Florida, Gainesville, FL., Hassoun H; Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY., Touzeau C; Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA), Institut National de la Santé et de la Recherche Médicale (INSERM), Centre National de la Recherche Scientifique (CNRS), Université d'Angers, Université de Nantes, Nantes, France.; Site de Recherche Intégrée sur le Cancer (SIRIC), Imaging and Longitudinal Investigations to Ameliorate Decision-making (ILIAD), Nantes, France.; Service d'hématologie Clinique, Centre Hospitalier Universitaire, Place Alexis Ricordeau, Nantes, France., Alegre A; Hospital Universitario La Princesa and Hospital Universitario Quironsalud, Madrid, Spain., Paner A; Rush University Medical Center, Chicago, IL., Maisel C; Baylor Scott & White Charles A. Sammons Cancer Center, Dallas, TX., Mazumder A; The Oncology Institute of Hope and Innovation, Glendale, CA., Raptis A; Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA., Moreb JS; Novant Health Hematology, Novant Health Forsyth Medical Center, Winston-Salem, NC., Anderson KC; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Laubach JP; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Thuresson S; Oncopeptides AB, Stockholm, Sweden., Thuresson M; Oncopeptides AB, Stockholm, Sweden., Byrne C; Oncopeptides AB, Stockholm, Sweden., Harmenberg J; Oncopeptides AB, Stockholm, Sweden., Bakker NA; Oncopeptides AB, Stockholm, Sweden., Mateos MV; Hospital Clínico Universitario de Salamanca/IBSAL/CIC, Salamanca, Spain. |
